Teva Pharmaceutical Industries Ltd (TEVA.TA)

TEVA.TA on Tel Aviv Stock Exchange

20,350.00
23 Oct 2014
Price Change (% chg)

230.00₪ (+1.14%)
Prev Close
20,120.00₪
Open
20,000.00₪
Day's High
20,350.00₪
Day's Low
20,000.00₪
Volume
552,473
Avg. Vol
356,677
52-wk High
20,350.00₪
52-wk Low
12,800.00₪

TEVA.TA

Chart for TEVA.TA

About

Teva Pharmaceutical Industries Ltd (Teva) is an Israel-based pharmaceutical and drug company. It develops, produces and markets generic drugs in all treatment categories. The Company has a pharmaceutical business, whose principal products include Copaxone and Azilect. Teva’s active pharmaceutical ingredient (API) business... (more)

Overall

Beta: 0.71
Market Cap (Mil.): ₪195,016.30
Shares Outstanding (Mil.): 953.25
Dividend: 121.00
Yield (%): 2.35

Financials

  TEVA.TA Industry Sector
P/E (TTM): 17.89 32.88 33.65
EPS (TTM): 11.44 -- --
ROI: 7.47 18.21 17.48
ROE: 11.47 18.89 18.31
Search Stocks

UPDATE 2-U.S. top court divided in battle over Teva MS drug patent

(Adds fresh details from oral argument, paragraphs 8-9, 11-12)

15 Oct 2014

U.S. Supreme Court justices divided over Teva patent battle

WASHINGTON, Oct 15 - The U.S. Supreme Court on Wednesday appeared closely divided as it weighed Teva Pharmaceutical Industries Ltd's high-profile fight with generic drug manufacturers over patent protections for Copaxone, its top-selling multiple sclerosis drug.

15 Oct 2014

U.S. top court hears Teva's multiple sclerosis drug patent fight

WASHINGTON - The U.S. Supreme Court on Wednesday is set to wade into Teva Pharmaceutical Industries Ltd's fight over patent protections for Copaxone, its top-selling multiple sclerosis drug, in one of the most important business cases of the justices' new term.

15 Oct 2014

U.S. top court hears Teva's multiple sclerosis drug patent fight

WASHINGTON, Oct 15 - The U.S. Supreme Court on Wednesday is set to wade into Teva Pharmaceutical Industries Ltd's fight over patent protections for Copaxone, its top-selling multiple sclerosis drug, in one of the most important business cases of the justices' new term.

15 Oct 2014

Actavis to buy Durata in a deal valued at about $675 million

- Generic drugmaker Actavis Plc said it would acquire Durata Therapeutics Inc in a deal valued at about $675 million to bolster its infectious disease portfolio.

06 Oct 2014

UPDATE 1-Actavis to buy Durata in a deal valued at about $675 mln

Oct 6 - Generic drugmaker Actavis Plc said it would acquire Durata Therapeutics Inc in a deal valued at about $675 million to bolster its infectious disease portfolio.

06 Oct 2014

Teva Pharm to halt R&D in cancer and women's health to cut costs

TEL AVIV - Teva Pharmaceutical Industries said it will stop research and development in areas such as oncology and women's health to cut costs, though it will maintain a commercial presence in these areas.

06 Oct 2014

Teva Pharm to halt R&D in cancer and women's health to cut costs

TEL AVIV, Oct 6 - Teva Pharmaceutical Industries said it will stop research and development in areas such as oncology and women's health to cut costs, though it will maintain a commercial presence in these areas.

06 Oct 2014

Gay marriage aside, business cases dominate U.S. high court docket

WASHINGTON - Gay marriage may be the most anticipated issue heading for the U.S. Supreme Court, but the justices also must tackle a host of business cases as they convene for their new term, including a patent battle involving Teva Pharmaceutical Industries Ltd.

03 Oct 2014

CORRECTED-BRIEF-Teva Pharmaceutical present new data on MS drug Copaxone

(Corrects company name in headline to Teva Pharmaceutical from Teva Pharmaceuticals. Also, removes incorrect reference to Copaxone as an experimental MS drug)

11 Sep 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: S&P Capital IQ – STARS Reports
$115.00
Provider: Stock Traders Daily
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks